Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Subgrouping a large U.S. sample of patients with fibromyalgia using the fibromyalgia impact questionnaire-revised

  • Pérez-Aranda, A.
  • Feliu-Soler, A.
  • Mist, S.D.
  • Jones, K.D.
  • López del Hoyo, Y.
  • Oliván-Arévalo, R.
  • Kratz, A.
  • Williams, D.A.
  • Luciano, J.V.
Fibromyalgia (FM) is a heterogeneous and complex syndrome; different studies have tried to describe subgroups of FM patients, and a 4-cluster classification based on the Fibromyalgia Impact Questionnaire-Revised (FIQR) has been recently validated. This study aims to cross-validate this classification in a large US sample of FM patients. A pooled sample of 6280 patients was used. First, we computed a hierarchical cluster analysis (HCA) using FIQR scores at item level. Then, a latent profile analysis (LPA) served to confirm the accuracy of the taxonomy. Additionally, a cluster calculator was developed to estimate the predicted subgroup using an ordinal regression analysis. Self-reported clinical measures were used to examine the external validity of the subgroups in part of the sample. The HCA yielded a 4-subgroup distribution, which was confirmed by the LPA. Each cluster represented a different level of severity: “Mild–moderate”, “moderate”, “moderate–severe”, and “severe”. Significant differences between clusters were observed in most of the clinical measures (e.g., fatigue, sleep problems, anxiety). Interestingly, lower levels of education were associated with higher FM severity. This study corroborates a 4-cluster distribution based on FIQR scores to classify US adults with FM. The classification may have relevant clinical implications for diagnosis and treatment response.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Impact of mindfulness and self-compassion on anxiety and depression: The mediating role of resilience [Impacto del mindfulness y de la autocompasión en la ansiedad y la depresión: rol mediador de la resiliencia]

  • Pérez-Aranda, A.
  • García-Campayo, J.
  • Gude, F.
  • Luciano, J.V.
  • Feliu-Soler, A.
  • González-Quintela, A.
  • López-del-Hoyo, Y.
  • Montero-Marin, J.
Background/Objective ‘Third-wave’ psychotherapies have shown effectiveness for treating psychopathological symptoms such as anxiety and depression. There is burgeoning interest in examining how these therapies’ core constructs produce their therapeutic benefits. This study explores the hypothetical mediating effect of resilience in the impact of mindfulness and self-compassion on anxiety and depressive symptoms. Method: Cross-sectional study design. The sample consisted of 860 Spanish general population participants. The measures included the Mindful Attention Awareness Scale (MAAS), the Self-Compassion Scale (SCS-12), the Connor-Davidson Resilience Scale (CD-RISC) and the Goldberg Anxiety and Depression Scale (GADS). Bivariate correlations were calculated, and path analysis models were performed. Results: Significant correlations were found between the study variables, always in the expected direction (all p values <.001). The path analysis models showed significant direct effects of mindfulness and self-compassion on anxiety and depression symptoms, but the only significant indirect effects through resilience were found on depression (MAAS: ß = -.05, 95% CI = -.11 to -.02; SCS-12: ß = -.06, 95% CI = -.33 to -.07). Conclusions: Resilience might partially mediate the effect of mindfulness and self-compassion on depression, but not on anxiety.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mindfulness-Based Program Plus Amygdala and Insula Retraining (MAIR) for the Treatment of Women with Fibromyalgia, a Pilot Randomized Controlled Trial

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Gasión, Virginia
  • Navarro-Gil, Mayte|||0000-0003-4842-0453
  • Morillo, Héctor|||0000-0002-9852-2776
  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Borràs, Xavier|||0000-0003-3972-1385
  • Tops, Mattie
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Garcia-Campayo, Javier|||0000-0002-3797-4218
  • Montero-Marín, Jesús|||0000-0001-5677-1662
  • Feliu-Soler, Albert|||0000-0003-2810-7670
The lack of highly effective treatments for fibromyalgia (FM) represents a great challenge for public health. The objective of this parallel, pilot randomized controlled trial (RCT) was two-fold: (1) to analyze the clinical effects of mindfulness plus amygdala and insula retraining (MAIR) compared to a structurally equivalent active control group of relaxation therapy (RT) in the treatment of FM; and (2) to evaluate its impact on immune-inflammatory markers and brain-derived neurotrophic factor (BDNF)in serum. A total of 41 FM patients were randomized into two study arms: MAIR (intervention group)and RT (active control group), both as add-ons of treatment as usual. MAIR demonstrated significantly greater reductions in functional impairment, anxiety, and depression, as well as higher improvements in mindfulness, and self-compassion at post-treatment and follow-up, with moderate to large effectsizes. Significant decreases in pain catastrophizing and psychological inflexibility and improvementsin clinical severity and health-related quality of life were found at follow-up, but not at post-treatment,showing large effect sizes. The number needed to treat was three based on the criteria of ≥50% Fibromyalgia Impact Questionnaire (FIQ) reduction post-treatment. Compared to RT, the MAIRshowed significant decreases in BDNF. No effect of MAIR was observed in immune-inflammatorybiomarkers (i.e., TNF-α, IL-6, IL-10, and hs-CRP). In conclusion, these results suggest that MAIR, as an adjuvant of treatment-as-usual (TAU), appears to be effective for the management of FM symptomsand for reducing BDNF levels in serum.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Social inequities in the impact of COVID-19 lockdown measures on the mental health of a large sample of the Colombian population (PSY-COVID study)

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Useche-Aldana, Bernardo
  • Ochoa, Pedro Pablo|||0000-0003-3035-8647
  • Rojas-Gualdrón, Diego Fernando|||0000-0002-2293-0431
  • Mateo Canedo, Corel|||0000-0002-0620-9257
  • Carmona Cervelló, Meritxell|||0000-0003-0907-9168
  • Crespo-Puig, Neus|||0000-0001-8036-6739
  • Selva Olid, Clara|||0000-0001-7390-9889
  • Muro Rodríguez, Anna|||0000-0002-1331-9921
  • Méndez Ulrich, Jorge Luis|||0000-0001-9718-0607
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
The identification of general population groups particularly vulnerable to the impact of COVID-19 lockdown measures on mental health and the development of healthcare policies are priority challenges in the current and future pandemics. This study aimed to identify the personal and social determinants of the impact of COVID-19 lockdown measures on mental health in a large sample of the Colombian population. In this cross-sectional study, an anonymous online survey was answered by 18,061 participants from the general population residing in Colombia during the first wave of the COVID-19 outbreak (from 20 May to 20 June 2020). The risk of depression, anxiety, and somatization disorders were measured using the Patient Health Questionnaire (PHQ-2), Generalized Anxiety Disorder Scale (GAD-2), and Somatic Symptom Questionnaire (SSQ-5), respectively. Overall, 35% of participants showed risk of depression, 29% of anxiety, and 31% of somatization. According to the analysis of social determinants of health, the most affected groups were people with low incomes, students, and young adults (18-29 years). Specifically, low-income young females were the most at-risk population group. These findings show how the lockdown measures affected the general population's mental health in Colombia and highlight some social risk factors in health.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Hernández-Negrín, Halbert
  • Borràs, Xavier|||0000-0003-3972-1385
  • Suso-Ribera, Carlos|||0000-0002-2655-1017
  • García Palacios, Azucena|||0000-0001-9250-8714
  • Muchart, Jordi
  • Munuera, Josep|||0000-0001-5154-1796
  • D'Amico, Francesco|||0000-0001-7995-826X
  • Maes, Michael|||0000-0002-2012-871X
  • Younger, Jarred W.
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Rozadilla-Sacanell, Antoni|||0000-0002-7555-189X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
There is evidence that low-dose naltrexone (LDN; <5.0 mg/day) reduces pain and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no randomised controlled trials with long-term follow-ups have been carried out. The INNOVA study will evaluate the add-on efficacy, safety, cost-utility and neurobiological effects of LDN for reducing pain in patients with FMS, with a 1-year follow-up. A single-site, prospective, randomised, double-blinded, placebo-controlled, parallel design phase III trial will be performed. Eligibility criteria include being adult, having a diagnosis of FMS and experiencing pain of 4 or higher on a 10-point numerical rating scale. Participants will be randomised to a LDN intervention group (4.5 mg/day) or to a placebo control group. Clinical assessments will be performed at baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3). The primary endpoint will be pain intensity. A sample size of 60 patients per study arm (120 in total), as calculated prior to recruitment for sufficient power, will be monitored between January 2022 and August 2024. Assessment will also include daily ecological momentary evaluations of FMS-related symptoms (eg, pain intensity, fatigue and sleep disturbance), and side effects via ecological momentary assessment through the Pain Monitor app during the first 3 months. Costs and quality-adjusted life years will be also calculated. Half of the participants in each arm will be scanned with MRI at T0 and T1 for changes in brain metabolites related to neuroinflammation and central sensitisation. Inflammatory biomarkers in serum will also be measured. This study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media and community engagement activities. .
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cost-Utility of Attachment-Based Compassion Therapy (ABCT) for Fibromyalgia Compared to Relaxation, A Pilot Randomized Controlled Trial

  • D'Amico, Francesco|||0000-0001-7995-826X
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Montero-Marín, Jesús|||0000-0001-5677-1662
  • Peñarrubía-María, María T.
  • Navarro-Gil, Mayte|||0000-0003-4842-0453
  • Van Gordon, William
  • Garcia-Campayo, Javier|||0000-0002-3797-4218
  • Luciano, Juan Vicente|||0000-0003-0750-1599
A recent study has supported the efficacy of Attachment-Based Compassion Therapy (ABCT) compared to relaxation (REL) for the management of fibromyalgia (FM). The main objective of this paper is to examine the cost-utility of ABCT compared to REL in terms of effects on quality-adjusted life years (QALYs) as well as healthcare costs. Forty-two Spanish patients with FM received 8 weekly group sessions of ABCT or REL. Data collection took place at pre- and 3-month follow-up. Cost-utility of the two treatment groups (ABCT vs. REL) was compared by examining treatment outcomes in terms of QALYs (obtained with the EQ-5D-3L) and healthcare costs (data about service use obtained with the Client Service Receipt Inventory). Data analyses were computed from a completers, ITT, and per protocol approach. Data analysis from the healthcare perspective revealed that those patients receiving ABCT exhibited larger improvements in quality of life than those doing relaxation, while being less costly 3 months after their 8-week treatment program had ended (completers: incremental cost M, 95% CI = €-194.1 (-450.3 to 356.1); incremental effect M, 95% CI = 0.023 QALYs (0.010 to 0.141)). Results were similar using an ITT approach (incremental cost M, 95% CI = €-256.3 (-447.4 to -65.3); incremental effect M, 95% CI = 0.021 QALYs (0.009 to 0.033)). A similar pattern of results were obtained from the per protocol approach. This RCT has contributed to the evidence base of compassion-based interventions and provided useful information about the cost-utility of ABCT for FM patients when compared to relaxation. However, the small sample size and short follow-up period limited the generalizability of the findings.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Efficacy, cost-utility and physiological effects of Acceptance and Commitment Therapy (ACT) and Behavioural Activation Treatment for Depression (BATD) in patients with chronic low back pain and depression, study protocol of a randomised, controlled trial including mobile-technology-based ecological momentary assessment (IMPACT study)

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Forero, Carlos G.|||0000-0002-5245-0076
  • Cristóbal Narváez, Paula|||0000-0001-8184-6347
  • Suso-Ribera, Carlos|||0000-0002-2655-1017
  • García Palacios, Azucena|||0000-0001-9250-8714
  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Pérez-Aranda, Adrián|||0000-0002-1602-3413
  • Andrés Rodríguez, Laura|||0000-0001-5133-9811
  • McCracken, Lance M.|||0000-0002-9734-0153
  • D'Amico, Francesco|||0000-0001-7995-826X
  • Estivill, Pere|||0000-0002-7917-6134
  • Carreras-Marcos, Bernat|||0000-0001-5224-1453
  • Montes-Pérez, Antonio
  • Comps, Olga|||0000-0002-0977-477X
  • Esteve, Montserrat|||0000-0003-2128-7859
  • Grasa, Mar
  • Rosa de la Cruz, Araceli|||0000-0001-6935-3785
  • Cuesta-Vargas, Antonio I.|||0000-0002-8880-4315
  • Maes, Michael|||0000-0002-2012-871X
  • Borràs, Xavier|||0000-0003-3972-1385
  • Edo Izquierdo, Sílvia|||0000-0002-6564-3475
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Castaño Asins, Juan Ramon|||0000-0001-6571-503X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
The IMPACT study focuses on chronic low back pain (CLBP) and depression symptoms, a prevalent and complex problem that represents a challenge for health professionals. Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment for Depression (BATD) are effective treatments for patients with persistent pain and depression, respectively. The objectives of this 12 month, multicentre, randomised, controlled trial (RCT) are (i) to examine the efficacy and cost-utility of adding a group-based form of ACT or BATD to treatment-as-usual (TAU) for patients with CLBP and moderate to severe levels of depressive symptoms; (ii) identify pre-post differences in levels of some physiological variables and (iii) analyse the role of polymorphisms in the FKBP5 gene, psychological process measures and physiological variables as mediators or moderators of long-term clinical changes. Participants will be 225 patients with CLBP and moderate to severe depression symptoms recruited at Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat, Spain) and Hospital del Mar (Barcelona, Spain), randomly allocated to one of the three study arms: TAU vs TAU+ACT versus TAU+BATD. A comprehensive assessment to collect clinical variables and costs will be conducted pretreatment, post-treatment and at 12 months follow-up, being pain interference the primary outcome measure. The following physiological variables will be considered at pretreatment and post-treatment assessments in 50% of the sample: immune-inflammatory markers, hair cortisol and cortisone, serum cortisol, corticosteroid-binding globulin and vitamin D. Polymorphisms in the FKBP5 gene (rs3800373, rs9296158, rs1360780, rs9470080 and rs4713916) will be analysed at baseline assessment. Moreover, we will include mobile-technology-based ecological momentary assessment, through the Pain Monitor app, to track ongoing clinical status during ACT and BATD treatments. Linear mixed-effects models using restricted maximum likelihood, and a full economic evaluation applying bootstrapping techniques, acceptability curves and sensitivity analyses will be computed. This study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu and Hospital del Mar. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media and various community engagement activities.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unhappy while depressed, examining the dimensionality, reliability and validity of the subjective happiness scale in a spanish sample of patients with depressive disorders

  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Diego-Adeliño, Javier de|||0000-0001-9708-2441
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Iraurgi, Ioseba|||0000-0002-0143-9539
  • Alemany Santamaría, Carlo|||0000-0001-8363-4786
  • Puigdemont, Dolors|||0000-0002-5729-0972
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Portella Moll, Maria J., 1975-|||0000-0002-2007-9516
  • Trujols, Joan|||0000-0003-0396-7105
Despite the considerable amount of research evidence on the significant role of subjective happiness on mental health, there is no psychometric study of the Subjective Happiness Scale (SHS) in psychiatric samples. This study was aimed at exploring the psychometric properties of the SHS in a Spanish sample of patients with depressive disorders. Participants were 174 patients with a depressive disorder (70% diagnosed as major depressive disorder) who completed the SHS, the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16), and the EQ-5D Visual Analogue Scale (EQ-5D VAS). Depressive symptoms were also assessed by means of the 17-item Hamilton Depression Rating Scale (HDRS17) and the Clinical Global Impression-Severity (CGI-S) Scale. Dimensionality, internal consistency reliability, construct validity, and responsiveness to change of the SHS were examined. Confirmatory factor analysis replicated the original one-factor structure of the scale. The SHS exhibited good-to-excellent results for internal consistency (α = 0.83) and for convergent [EQ-5D VAS (r = 0.71)] and divergent [QIDS-SR16 (r = -0.72), HDRS17 (r = -0.60) and CGI-S (r = -0.61)] construct validity. The ability of the SHS to differentiate between depression severity levels as well as its responsiveness to clinical change were both highly satisfactory (p < 0.001 in both cases). The SHS retained the soundness of psychometric properties showed in non-clinical samples in a sample of patients with depressive disorders, which supports its use as a reliable and valid outcome measure in the treatment of such disorders.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Peripheral immune aberrations in fibromyalgia, a systematic review, meta-analysis and meta-regression

  • Andrés Rodríguez, Laura|||0000-0001-5133-9811
  • Borràs, Xavier|||0000-0003-3972-1385
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Pérez-Aranda, Adrián|||0000-0002-1602-3413
  • Angarita-Osorio, Natalia|||0000-0001-8925-2754
  • Moreno-Peral, Patricia|||0000-0003-4130-9090
  • Montero-Marín, Jesús|||0000-0001-5677-1662
  • Garcia-Campayo, Javier|||0000-0002-3797-4218
  • Carvalho, André F.
  • Maes, Michael|||0000-0002-2012-871X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
The objective was to identify immune alterations in patients with fibromyalgia syndrome (FMS) compared to healthy controls (HC) using meta-analysis and meta-regression. Six electronic databases were searched for suitable original articles investigating immune biomarkers in FMS in comparison to HC. We extracted outcomes and variables of interest, such as mean and SD of peripheral blood immune biomarkers, age or sex. A random-effects model with restricted maximum-likelihood estimator was used to compute effect sizes (standardized mean difference and 95% CI, Hedges' g) and meta-analysis, group meta-analysis and meta-regressions were conducted. Forty-three papers were included in this systematic review, of which 29 were suitable for meta-analysis. Interleukin (IL)-6 (g = 0.36 (0.09-0.63); I2 = 85.94; p = 0.01), IL-4 (g = 0.50 (0.03-0.98); I2 = 81.87; p = 0.04), and IL-17A (g = 0.53 (0.00-1.06); I2 = 87.15; p = 0.05), were significantly higher in FMS compared to HC while also combinations of cytokines into relevant phenotypes were significantly upregulated including M1 macrophage (g = 0.23 (0.03-0.43); I2 = 77.62; p = 0.02), and immune-regulatory (g = 0.40 (0.09-0.72); I2 = 84.81; p = 0.01) phenotypes. Heterogeneity levels were very high and subgroup and meta-regression analyses showed that many covariates explained part of the heterogeneity including medication washout, sex, time of blood sampling and exclusion of patients with major depressive disorder. In conclusion, FMS is accompanied by a disbalance between upregulated pro-inflammatory (M1 and Th-17) and immune-regulatory cytokines although effect sizes are small-to-moderate. Based on our results we provide specific methodological suggestions for future research, which should assess Th-1, Th-17, chemokines, and Th-2 phenotypes while controlling for possible confounding variables specified in this study.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effectiveness of a Multicomponent Treatment Based on Pain Neuroscience Education, Therapeutic Exercise, Cognitive Behavioral Therapy, and Mindfulness in Patients With Fibromyalgia (FIBROWALK Study), A Randomized Controlled Trial

  • Serrat López, Mayte|||0000-0002-5591-9407
  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Almirall, Míriam|||0000-0002-4874-8013
  • Musté, Marta|||0000-0002-0748-1121
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Méndez Ulrich, Jorge Luis|||0000-0001-9718-0607
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
  • Luciano, Juan Vicente|||0000-0003-0750-1599
Objective. The purpose of this study was to evaluate the effectiveness of a 12-week multicomponent treatment based on pain neuroscience education, therapeutic exercise, cognitive behavioral therapy, and mindfulness-in addition to treatment as usual-compared with treatment as usual only in patients with fibromyalgia. Methods. This randomized controlled trial involved a total of 272 patients who were randomly assigned to either multicomponent treatment (n = 135) or treatment as usual (n = 137). The multicomponent treatment (2-hour weekly sessions) was delivered in groups of 20 participants. Treatment as usual was mainly based on pharmacological treatment according to the predominant symptoms. Data on functional impairment using the Revised Fibromyalgia Impact Questionnaire as the primary outcome were collected as were data for pain, fatigue, kinesiophobia, physical function, anxiety, and depressive symptoms (secondary outcomes) at baseline, 12 weeks, and, for the multicomponent group only, 6 and 9 months. An intention-to-treat approach was used to analyze between-group differences. Baseline differences between responders (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Does practice make perfect?, functional connectivity of the salience network and somatosensory network predicts response to mind-body treatments for fibromyalgia

  • Medina, Sonia|||0000-0001-8883-6520
  • O'Daly, Owen G.|||0000-0001-5690-1252
  • Howard, Matthew A.|||0000-0002-9359-3057
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Luciano, Juan Vicente|||0000-0003-0750-1599
BACKGROUND: Mind-body treatments can improve coping mechanisms to deal with pain, improve the quality of life of patients with fibromyalgia syndrome (FMS), and reduce perceived pain in some cases. However, responses to these treatments are highly variable, the mechanisms underpinning them remain unclear, and reliable predictors of treatment response are lacking. We employed resting-state blood oxygen level-dependent (rsBOLD) functional magnetic resonance imaging (fMRI) to examine changes in brain functional connectivity (FC) following mind-body treatment that may relate to and predict pain relief. METHODS: We recruited patients with FMS who underwent either mindfulness-based stress reduction (MBSR; n = 18) or a psychoeducational program (FibroQoL; n = 22) and a treatment-as-usual FMS group (TAU; n = 18). We collected rsBOLD data, alongside subjective pain, anxiety, depression, and catastrophizing measures prior to and following treatments. We examined behavioral changes and FC changes in the salience network (SN) and sensorimotor network (SMN) and performed regression analyses to identify predictors for treatment response. RESULTS: The MBSR and FibroQoL groups experienced significant reductions in pain catastrophizing. After treatment, the FC of the sensorimotor cortex with the rest of the SMN became significantly reduced in the MBSR group compared to the TAU group. The FC between the SN and the SMN at baseline was negatively correlated with pain reductions following MBSR but positively correlated with pain reductions in the FibroQoL group. These results yielded large to very large effect sizes. Following MBSR, only for those patients with lower baseline SMN-SN FC, minutes of mindfulness practice were positively associated with clinical improvement (small to medium effect size). CONCLUSIONS: Different mind-body treatments are underpinned by discrete brain networks. Measures of the functional interplay between SN and SMN have the potential as predictors of mind-body treatment response in patients with FMS.